Chongqing Lummy Stock Hits Day Low of CNY 5.80 Amid Price Pressure

Chongqing Lummy Pharmaceutical Co., Ltd. has experienced a significant decline today, with the stock dropping by 5.83% and reaching an intraday low of CNY 5.80. This performance stands in contrast to the broader market, as the China Shanghai Composite index fell by only 2.04% on the same day. Over the past week, Chongqing Lummy has seen a notable decrease of 8.92%, while its monthly performance reflects a decline of 9.63%. Despite a strong yearly performance of 62.12%, the company has faced challenges in recent quarters, reporting negative net profit and operating cash flow figures. The company’s net sales have contracted at an annual rate of 13.87% over the last five years, indicating ongoing difficulties in achieving sustainable growth. Chongqing Lummy's market capitalization stands at CNY 5,141 million, categorizing it as a mid-cap company within the pharmaceuticals and biotechnology sector. The stock's current trading conditions suggest heightened risk, particularly given its negative return on equity and poor management efficiency metrics.